Literature DB >> 1671755

Allelic loss on chromosome 11 in hereditary and sporadic tumors related to familial multiple endocrine neoplasia type 1.

A E Bale1, J A Norton, E L Wong, J S Fryburg, P N Maton, E H Oldfield, E Streeten, G D Aurbach, M L Brandi, E Friedman.   

Abstract

Familial multiple endocrine neoplasia type 1 (FMEN1) is an autosomal dominant disorder characterized by tumors of the parathyroid glands, pancreatic islets, and anterior pituitary. The gene for this disease maps to chromosome 11q12-11q13, and allelic loss in this region has been shown in both sporadic and FMEN1-related parathyroid tumors. FMEN1-related pancreatic islet tumors, and rarely in sporadic anterior pituitary tumors. We tested for allelic loss at 7 loci on chromosome 11 in 17 tumors outside the parathyroid. We found loss of heterozygosity in 2 of 2 FMEN1-related benign pancreatic islet tumors but in none of 8 informative sporadic islet tumors (P = 0.02) including 5 malignant gastrinomas. Of 3 islet tumors from patients who had some but not all features of FMEN1, one showed allelic loss for 5 of 5 informative restriction fragment length polymorphisms, and the other 2 retained heterozygosity for all informative markers. A bronchial carcinoid from an FMEN1 patient and 3 sporadic anterior pituitary tumors showed no allelic loss. These data provide new evidence that many sporadic pancreatic islet neoplasms, even when malignant, do not develop through homozygous inactivation of the MEN1 gene.

Entities:  

Mesh:

Year:  1991        PMID: 1671755

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  21 in total

1.  11q13 allelic imbalance discriminates pulmonary carcinoids from tumorlets. A microdissection-based genotyping approach useful in clinical practice.

Authors:  S D Finkelstein; T Hasegawa; T Colby; S A Yousem
Journal:  Am J Pathol       Date:  1999-08       Impact factor: 4.307

2.  Mapping of 262 DNA markers into 24 intervals on human chromosome 11.

Authors:  A Tanigami; T Tokino; S Takiguchi; M Mori; T Glaser; J W Park; C Jones; Y Nakamura
Journal:  Am J Hum Genet       Date:  1992-01       Impact factor: 11.025

3.  [Tumors of the endocrine pancreas].

Authors:  M Anlauf; B Sipos; G Klöppel
Journal:  Pathologe       Date:  2005-02       Impact factor: 1.011

4.  Controversies and advances in primary hyperparathyroidism.

Authors:  J A Norton
Journal:  Ann Surg       Date:  1992-04       Impact factor: 12.969

Review 5.  The use of molecular technology in the differentiation of pancreatic cancer and chronic pancreatitis.

Authors:  S R Bramhall
Journal:  Int J Pancreatol       Date:  1998-04

6.  Genetic studies of thymic carcinoids in multiple endocrine neoplasia type 1.

Authors:  B T Teh; N K Hayward; M K Walters; J J Shepherd; S Wilkinson; M Nordenskjold; C Larsson
Journal:  J Med Genet       Date:  1994-03       Impact factor: 6.318

7.  Genomic instability in pituitary adenomas.

Authors:  Janusz Szymas; Karsten Schluens; Wlodzimierz Liebert; Iver Petersen
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

8.  Mapping eight new polymorphisms in 11q13 in the vicinity of multiple endocrine neoplasia type 1: identification of a new distal recombinant.

Authors:  C M Smith; S A Wells; D S Gerhard
Journal:  Hum Genet       Date:  1995-10       Impact factor: 4.132

9.  Improved carrier testing for multiple endocrine neoplasia, type 1, using new microsatellite-type DNA markers.

Authors:  S Kytölä; J Leisti; R Winqvist; P Salmela
Journal:  Hum Genet       Date:  1995-10       Impact factor: 4.132

Review 10.  [Hyperplasia and tumors of the parathyroid glands].

Authors:  S-Y Sheu; F Otterbach; A Frilling; K W Schmid
Journal:  Pathologe       Date:  2003-06-19       Impact factor: 1.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.